



Cargo encapsulated hepatitis E virus-like particles for anti-HEV antibody detection

Akhilesh Babu Ganganboina^a, Kenshin Takemura^b, Wenjing Zhang^c, Tian-Cheng Li^c, Enoch Y. Park^{a,b,*}

^a Research Institute of Green Science and Technology, Shizuoka University, 836 Ohya Suruga-ku, Shizuoka, 422-8529, Japan

^b Department of Bioscience, Graduate School of Science and Technology, Shizuoka University, 836 Ohya Suruga-ku, Shizuoka, 422-8529, Japan

^c Department of Virology 2, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo, 208-0011, Japan

ARTICLE INFO

Keywords:

Virus-like particles
Quantum dots
Antibody
Fluorescence
Infectious disease diagnosis
Hepatitis E virus

ABSTRACT

Viral capsid-nanoparticle hybrid structures incorporating quantum dots (QDs) into virus-like particles (VLPs) constitute an emerging bioinspired type of nanoarchitecture paradigm used for various applications. In the present study, we packed inorganic QDs in vitro into the hepatitis E virus-like particle (HEV-LP) and developed a fluorometric biosensor for HEV antibody detection. Firstly, for the preparation of QDs-encapsulated HEV-LPs (QDs@HEV-LP), the HEV-LPs produced by a recombinant baculovirus expression system were disassembled and reassembled in the presence of QDs using the self-assembly approach. Thus, the prepared QDs@HEV-LP exhibited excellent fluorescence properties similar to QDs. Further, in the presence of HEV antibodies in the serum samples, when mixed with QDs@HEV-LP, bind together and further bind to anti-IgG-conjugated magnetic nanoparticles (MNPs). The target-specific anti-IgG-MNPs and QDs@HEV-LP enrich the HEV antibodies by magnetic separation, and the separated QDs@HEV-LP-bound HEV antibodies are quantified by fluorescence measurement. This developed method was applied to detect the HEV antibody from sera of HEV-infected monkey from 0 to 68 days-post-infection and successfully diagnosed for HEV antibodies. The viral RNA copies number from monkey fecal samples by RT-qPCR was compared to the HEV antibody generation. This study first used QDs-encapsulated VLPs as useful fluorescence emitters for biosensing platform construction. It provides an efficient route for highly sensitive and specific antibody detection in clinical diagnosis research.

1. Introduction

Nanoparticles and biomaterial conjugates exhibit several highly beneficial properties that can be used for biosensing (Michalet et al., 2005; Tagit et al., 2017; Yang et al., 2020). Viral capsids have drawn considerable interest in the field of nanobiology due to their symmetrical structure, nanoscale size, and controllable self-assembly with easy modifications (Herbert et al., 2020; Sasaki et al., 2020). The virus-based nanoparticles, integrating the bio-activities of virus capsids with nanoparticle functions, are a recently emerging class of bio-nanomaterials with many potential applications, such as theranostics, bio-imaging, biosensing, and advanced synthesis of nanomaterial (Brasch et al., 2017; Li et al., 2019a; Liu et al., 2012; Yan et al., 2015). One application is the continuous monitoring of viral infection, which might prevent the spread of viral infection. Inspired by nature, virus-based nanoparticles

encapsulated with various materials like inorganic nanoparticles, proteins, nucleic acids, and small molecule drugs are developed to fabricate new kind of nanostructures (Chen et al., 2005; Dixit et al., 2006; Li et al., 2011, 2019a).

The primary technique for encapsulation is the reassembly of virus-like particles (VLPs) in the presence of materials of interest. Initially, VLPs are dissociated into subunit oligomers (building blocks) by treating with suitable buffers, followed by mixing the oligomers with cargoes and buffer exchange to accelerate the VLPs reassembly encapsulating the cargo (Aniagyei et al., 2009; Brasch et al., 2017). Dragnea et al. (2003). Demonstrated a similar self-assembly technique encapsulating gold nanoparticles in the Brome mosaic virus's capsids. VLPs obtained from bacteriophage MS2, Qbeta, and hepatitis B virus (HBV) are highly stable and have received significant attention in nanotechnology (Liu et al., 2012; Wen and Steinmetz 2016). Recent developments in preparing

* Corresponding author. Research Institute of Green Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka, 422-8529, Japan.

E-mail addresses: akhilesh.babu.ganganboina@shizuoka.ac.jp (A.B. Ganganboina), takemura.kenshin.16@shizuoka.ac.jp (K. Takemura), zwjviolin@foxmail.com (W. Zhang), lite@nih.go.jp (T.-C. Li), park.enoch@shizuoka.ac.jp (E.Y. Park).

<https://doi.org/10.1016/j.bios.2021.113261>

Received 26 January 2021; Received in revised form 31 March 2021; Accepted 15 April 2021

Available online 22 April 2021

0956-5663/© 2021 Elsevier B.V. All rights reserved.

multifunctional nanomaterials pave the way for integrating various detection methodologies (Chowdhury et al., 2018; Dang et al., 2020; Dutta Chowdhury et al., 2018; Ganganboina and Doong 2019). The encapsulation of nanomaterials in VLPs from different viruses can improve biocompatibility, making VLPs attractive nanocapsule for various nanomaterials' encapsulation (Ma et al., 2012). QDs-encapsulated VLPs exhibit strong luminescence allowing them to be used as promising luminescent bioprobes. However, the insufficient focus has been paid on applying virus-based nanoparticles loaded with various cargoes concerning prepared virus-based nanoparticles' stability.

Antibodies are well known as essential biomarkers for many disorders, including infectious diseases, autoimmune diseases, and allergies (Arts et al., 2016; Lei et al., 2018). Detection of antibodies in low concentrations with straight forward using highly reliable assays urgently needs appropriate clinical treatment. However, immobilized antigen on solid supports leads to the physical deformation of antigen, hampering the detection sensitivity of several disease-specific antibodies in enzyme-linked immunosorbent assays (ELISAs), lateral flow assays, or protein microarrays (Ganganboina et al., 2020a; Tsai et al., 2016; Zhang et al., 2014). In addition, the uncertain orientation of antigens deposited can mask essential epitopes for antibody conjugation (Iverson et al., 2002). Solution-phase techniques like radioimmunoassay (RIA) is the current gold standard antibody detection method with significant advantages. The highly sensitive RIAs use highly radioactive reagents and demand laborious washing and centrifugation steps. In addition, the poor multiplexing ability of RIAs limits the application for development of new antibody biomarkers (Qi and Zhang, 2020). As a result, currently, existing methods do not satisfy the need for an assay that maintains the native conformation of antigens and allows efficient, multiplexed identification of their related antibodies. Such an approach will significantly enhance disease identification diagnostic techniques confirming the sensitive antibody biomarkers and promoting under-explored biomarkers in multiple human pathologies.

Hepatitis E virus (HEV) is a non-enveloped RNA virus that causes self-limiting acute process illness with reported chronic hepatitis cases. HEV causes chronic infections in immunocompromised people and is transfusion-transmissible (Liu et al., 2020). The World Health Organization identifies the HEV infection as a public health problem in several developing countries, especially among at-risk communities such as pregnant women, displaced persons living in camps, and epidemic situations (Ganganboina et al., 2020c; World Health Organization, 2015). The serological diagnosis of acute HEV infection is based on identifying HEV-specific IgM antibodies or recent reoccurrence or dramatic increase in virus-specific IgG antibody titers. However, commercially available HEV antibody assays show significant disparities in sensitivity and specificity (Wenzel et al., 2013; Zafrullah et al., 2018). This highlights the need for accurate testing to diagnose acute or past HEV infections.

To overcome the limitations of the existing antibody detection methods, a sensing platform using QDs-encapsulated VLPs has been developed. As a new nano-biomaterial class, VLPs are considered possible biological carriers to encapsulate QDs due to their high similarity in conformation and natural virus properties, which aid in biosensing. In this study, HEV-like particles (HEV-LPs) are primarily used as a model to apply the principle of QD encapsulation to HEV-based protein cages. A robust and sensitive assay for the detection of HEV antibodies was developed using the QD-encapsulated HEV-LPs. VLPs contain protein sequences that are related to the binding between virus and cell surface receptors. Thus, VLPs can mimic native virus binding against its specific antibody. In addition, the solution phase detection method developed in this study, maintains the native conformation of antigens. It avoids the unexpected orientation, which can withhold the essential epitopes for antibody conjugation and prevent antigens physical deformation after immobilization on solid supports. The optimized fluorometric biosensing platform achieved high sensitivity for the anti-HEV antibody assay. Significantly, this study not only revealed QDs-

encapsulated HEV-LPs (QDs@HEV-LPs) as promising fluorescence emitters for biosensing platform development but also opened a new avenue for highly sensitive and selective antibody detection in disease diagnosis and clinical research.

2. Materials and methods

2.1. Preparation of CdSeTeS quantum dots and biomaterials

The quaternary alloyed CdSeTeS QDs are synthesized using a one-step organometallic hot-injection technique by modifying the synthesis method discussed in our previous study (Adegoke et al., 2015).

Anti-white spot syndrome virus (WSSV) VP28 antibody [ab26935] were purchased from Abcam Inc. (Cambridge, UK). Anti-influenza virus (IFV) antibody (New Caledonia/20/99) (H1N1) from IFV was purchased from Prospec-Tany Techno Gene Ltd. (Rehovot, Israel). Anti-norovirus (NoV) antibody broadly reactive to genogroup II (NS14 Ab) were provided by Prof. T. Suzuki of Hamamatsu University School of Medicine (Hamamatsu, Japan). Anti-S protein antibody of SARS-CoV-2 were purchased from GeneTex, Inc. CA, USA. Anti-NS1 protein antibody for zika virus (ZIKV) (MAB12312-100) and anti-E1 protein of Chikungunya virus (CHIKV) (NAT41557-100) were purchased from the Native Antigen company (Oxford, United Kingdom).

2.2. Construction of a recombinant baculovirus

Genotype 1 (G1) HEV strain (GenBank accession no.: DQ079624) was isolated from an acute hepatitis E patient in Myanmar in 1986. PCR-amplified DNA fragments with N-terminal 111 amino acid deletions encoded by ORF2 with two primers, HEV-D13 (5'-AAGGATC-CATGGCGTGCTCCAGCCCATGACACCCGCCAGT-3) and HEV-U14 (5'-GGTCTAGACTATAACTCCCGAGTTTACCACCTTCATCTT-3). The product obtained from PCR included the XbaI site after the stop codon and the BamHI site before the start codon. Purification of the PCR product was performed using a QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and cloned into TA cloning vector pCR2.1 (Invitrogen, Carlsbad, CA, USA), digested with BamHI and XbaI, and ligated with a baculovirus transfer vector, pVL1393 (Pharming, San Diego, CA, USA), to yield plasmid pVL5480/7126. The transition plasmid pVL5480/7126 to the recombinant baculovirus was combined with baculoGold (Pharming) and lipofectin (GIBCO-BRL, Gaithersburg, MD, USA) and transfected into Sf9 insect cells (Riken Cell Bank, Tsukuba, Japan). Cells were incubated in TC-100 medium (GIBCO-BRL) complemented with 10% fetal bovine serum (FBS) at 26.5 °C and 0.26% tryptose phosphate broth (Difco Laboratories, Sparks, MD, USA). Recombinant baculovirus was plaque-purified three times in Sf9 cells and identified as Ac5480/712657 (Li et al., 1997).

2.3. Expression and purification of HEV-LPs

Cells from the *Trichoplusia ni*, BTL-Tn 5B1-4 (Tn5) cell line, were infected with the Ac5480/7126 at a multiplicity of infection 10 and grown at 26.5 °C in EX-CELL 405 medium (JRH Biosciences, Lenexa, KS, USA). Later, the Tn5 cells were harvested at 7 days-post-infection (dpi). By centrifugation for 60 min at 10,000×g, the intact cells and cell debris were removed. The supernatant was then separated by spinning in a Beckman SW32Ti rotor at 100,000×g for 3 h, and the resulting pellet was resuspended at 4 °C overnight in EX-CELL 405 medium. Further, 4.5 mL of each sample was combined with 2.1 g of CsCl and centrifuged with a Beckman SW55Ti rotor at 100,000 g for 24 h at 10 °C. The gradient was divided into 250-μL aliquots and weighted each fraction to approximate the buoyant density and isopycnic value. To separate the CsCl, each fraction was diluted with an EX-CELL 405 medium and centrifuged in a Beckman TLA55 rotor for 2 h at 100,000 g (Yang et al., 2017).

2.4. Rabbit anti-G3 HEV IgG antibody generation

Japanese white rabbits were immunized with 500 µg of G3 HEV-LPs by percutaneous injection. In addition, booster injections were given at 4 and 6 weeks after the first injection with half doses of G3 HEV-LPs. All of the injections, including booster injections, were administered without using adjuvant. Blood was collected from immunized animals 3 weeks after the last injection, and the anti-HEV-LPs IgG was purified by protein G column (Li et al., 2011).

2.5. Preparation of QDs-encapsulated HEV-LPs

The QDs are encapsulated into HEV-LPs according to a procedure described previously with slight modifications (Takamura et al., 2004). A 180 µl of a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA, and 20 mM dithiothreitol was used to disrupt the purified VLPs (50 µg). After 30 min of incubation at room temperature, various concentrations of QDs in 50 mM Tris-HCl buffer (pH 7.5) and 150 mM NaCl were added to the above mixture. The disturbed VLP preparation was regenerated by incubation for 1 h, with increased CaCl_2 concentrations up to 5 mM. VLPs were purified by ultracentrifugation and resuspended in 10 mM potassium-MES buffer (pH 6.2). After negative staining, the development of QDs@HEV-LPs structures was confirmed by electron microscopy at each step.

The unencapsulated QDs were removed by dialysis. Various mixtures were transferred into a 10 kDa dialysis bag, placed in a buffer (40 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl_2 , pH 7.4), and stirred overnight at 4 °C. The dialysis bag solution was then collected and centrifuged at 20000×g, 4 °C for 1 h, to spin down the QDs@HEV-LPs.

2.6. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting

The protein of HEV-LPs was separated by SDS-PAGE using 5–20% e-Page (ATTO, Tokyo) and then stained with Coomassie blue. For western blotting, the separated protein was electrophoretically transferred onto a nitrocellulose membrane. The membrane was blocked with 5% skim milk in 50 mM Tris-HCl (pH 7.4) containing 150 mM NaCl, and then incubated with 1:2000 diluted rabbit anti-HEV-LPs antibody. Detection of the rabbit IgG antibody was achieved using alkaline phosphatase-conjugated affinity-purified goat anti-rabbit IgG (H+L) (1:1000 dilution) (Chemicon, USA). Nitroblue tetrazolium chloride and 5-Bromo-4-chloro-3-indolyl phosphate P-toluidine were used as coloring agents (Bio-Rad Laboratories, Hercules, CA).

2.7. Preparation of amine-functionalized magnetic nanoparticles (MNPs)

Amine-functionalized MNPs (Amine-MNPs) were synthesized according to the method described by Robinson and Stevenson (2013) with some modifications. A solution of $\text{NH}_2\text{C}_6\text{H}_{12}\text{NH}_2$ (2.2 g), KAc (0.78 g), and $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ (0.33 g) in ethylene glycol (10 mL) was transferred into a Teflon-lined autoclave and reacted at 180 °C for 5 h. The precipitated amine-MNPs were then rinsed with ethanol and water (3 times each).

2.8. Preparation of anti-rabbit IgG antibody-conjugated MNPs and anti-monkey IgG antibody-conjugated MNPs

The anti-rabbit-IgG-conjugated amine-MNPs were prepared using EDC/NHS reaction mentioned in our previous work (Ganganboina et al., 2020b). Briefly, the prepared amine-MNPs in PBS were mixed with 0.1 M EDC to activate the carboxylic group to ester-intermediate form and was mixed with excess 0.4 M NHS and 5.1 µg of anti-rabbit (R)-IgG antibody solution. Finally, the mixture was then stirred overnight at 7 °C. The anti-R-IgG antibody-conjugated MNPs (Anti-R-IgG@MNPs) were separated magnetically from the mixture of unreacted chemicals,

and were stored at 4 °C for further use. Like the procedure mentioned above, anti-monkey (M)-IgG antibody-conjugated MNPs (Anti-M-IgG@MNPs) were prepared, replacing the anti-R-IgG antibody with anti-M-IgG antibody (Nordic-MUBio, Susteren, Netherlands) and used for detecting the HEV antibodies in samples obtained from cynomolgus monkey.

2.9. Inoculation of cynomolgus monkeys and sample collection

Nonhuman primates, including cynomolgus monkeys, are widely used in animal models to study HEV infection, pathogenesis, and vaccine trials. The sensor performance has been tested G5 HEV-infected cynomolgus monkey (Li et al., 2019b). A 10-year old male cynomolgus monkey, which was negative for HEV RNA by a nested broad-spectrum RT-PCR and negative for anti-HEV antibodies were intravenously inoculated with 1 mL of the G5 HEV through the femoral vein. The serum samples were collected 2 times per week until 5 weeks p.i. and then collected weekly until 10 weeks p.i. and used to detect anti-G5 HEV IgG antibodies. The fecal samples were collected daily until 35 dpi and then collected weekly and used to detect the G5 HEV RNA using RT-PCR.

2.10. Characterizations

Transmission electron microscopy (TEM), dynamic light scattering (DLS), X-ray diffraction (XRD) patterns, X-ray photoelectron spectroscopy (XPS), UV/Vis absorption spectra, and fluorescence measurements were performed using the instruments described in our previous studies (Dutta Chowdhury et al., 2018).

2.11. Detection of anti-HEV antibodies

QD@HEV-LPs were mixed with different concentrations of the anti-HEV Rabbit IgG antibodies obtained from Japanese white rabbits immunized with HEV and further incubated for 20 min. Later, anti-R-IgG-conjugated-MNPs were mixed with the above solution and further incubated for 20 min. Magnetic separation was applied to capture anti-R-IgG@MNPs/anti-HEV antibody/QD@HEV-LPs complex. The anti-IgG@MNPs/anti-HEV antibody/QD@HEV-LPs complex was separated magnetically, followed by washing several times with phosphate-buffered saline (PBS) to remove all unbound QD@HEV-LPs. After the separation, the mixture was re-dispersed into fresh 100 µL PBS buffer, and the fluorescence intensity was measured using a fluorescence spectrometer (Infinite F200 M; TECAN, Ltd, Männedorf, Switzerland). The sample solution was excited at 450 nm, and the fluorescence intensity was measured in a range of 580–720 nm. To monitor anti-HEV antibodies in serum samples from HEV-infected cynomolgus monkeys, a similar procedure as mentioned above was performed, however, replacing anti-M-IgG-conjugated to MNPs (anti-M-IgG@MNPs) instead of anti-R-IgG@MNPs.

2.12. Quantitative real-time RT-PCR for detection of G5 HEV

The RNA extraction was carried out by a MagNA Pure LC System with a MagNA Pure LC Total Nucleic Acid isolation kit (Roche Applied Science, Mannheim, Germany). A TaqMan assay for determination of the G5 HEV RNA copy number was performed using a 7500 FAST Real-Time PCR System (Applied Biosystems, Foster City, CA) with TaqMan Fast Virus 1-step Master Mix (Applied Biosystems) and the forward primer 5'-CCATGGAGGCCACACAGTT-3' (nt 24–42), a reverse primer 5'-TCAGGGCGAAAGACCAGCTG-3' (nt 185–204), and probe 5'-FAM-CCAACTCCGCCTTGGCGAATGC-TAMRA-3' (nt 96–117). One-step quantitative RT-PCR (RT-qPCR) was performed for 5 min at 50 °C and for 20 s at 95 °C, followed by 50 cycles of 3 s at 95 °C and 30 s at 60 °C. A 10-fold serial dilution of the capped G5 HEV RNA, 10 to 107 copies, was used as the standard. Amplification data were collected and analyzed with Sequence Detector software version 1.3 (Applied Biosystems).

3. Results and discussion

3.1. Working principle


Scheme 1 exhibits the newly developed fluorometric sensing system's basic concept for the reliable and ultrasensitive detection of anti-HEV IgG antibody. It consists of QDs@HEV-LPs and anti-M-IgG@MNPs that can precisely identify anti-HEV antibody and form the complex structure of QDs@HEV-LPs/Anti-HEV antibody/Anti-M-IgG@MNPs, as shown in **Scheme 1**. Following the interaction, the nanoconjugates of QDs@HEV-LPs/Anti-HEV/Anti-M-IgG@MNPs are separated magnetically from the excess reagents and other interfering substances. In thus formed sandwich-like structure with QDs@HEV-LPs/Anti-HEV antibody/Anti-M-IgG@MNPs, Anti-M-IgG@MNPs isolate the target antibodies, and QDs@HEV-LPs amplify the signal.

Owing to the existence of QDs within the HEV-LPs, the QDs@HEV-LPs have excellent fluorescence efficiency. This fluorescence is used as a signal to ensure the sensitivity and accuracy of sensing the target virus. Thus, separated complex dispersed into a fresh buffer is used to record the fluorescence intensity. The increase in the target antibody concentration facilitates an increased number of QDs@HEV-LPs with the target antibody and further with anti-R-IgG@MNPs, increasing fluorescence intensity. The absence of target antibody cannot form the target/QDs@HEV-LPs complex resulting in the negligible presence of QDs@HEV-LPs in the separated mixture causing no change in fluorescence intensity. The developed QDs@HEV-LPs-based sensor will provide superior accuracy, diversity, and flexibility to fulfill the detection needs in diverse regions and diverse circumstances. Encapsulated QDs inside the HEV-LPs are not influenced by the external matrix allowing the identification of sensitive fluorometric signal readings and the target's magnetic separation, benefit the detection capabilities in low analyte concentration and complex matrix.

3.2. Characterizations of QDs, HEV-LPs, and QDs@HEV-LPs

The synthesis of QD@HEV-LPs involves three steps, as illustrated in **Fig. 1a**: i) synthesis of QDs and preparation of HEV-LPs, ii) disassembly of HEV-LPs, and iii) reassembly of HEV-LPs in the presence of QDs. **Fig. 1b** shows the TEM image of CdSeTeS QDs. For the preparation of HEV-LPs, the culture medium of Ac5480/7126-infected Tn5 cells is collected at 7 dpi, and CsCl-gradient centrifugation was performed to purify p53 (Li et al., 1997, 2011). The TEM images of HEV-LPs showed uniformly dispersed spherical particles with an average diameter of approximately 35 nm (**Fig. 1c**). The morphology of these particles is similar to that of HEV native particles. The purified HEV-LPs are disassembled by reducing disulfide bonds using DTT (**Fig. 1d**). Further, when calcium ions were introduced to the disassembled HEV-LPs mixture in the presence of QDs, the QDs are encapsulated into the refolded HEV-LPs (**Fig. 1e**). As observed from the TEM images, no significant morphological difference has occurred due to the HEV-LPs disrupting and refolding process.

The synthesized CdSeTeS QDs are circular, with particle size between 3 and 8 nm and an average particle diameter of 5 nm (**Fig. 1f**). The HEV-LPs are morphologically uniform with small size distribution and a mean diameter of 25 nm (**Fig. 1g**). TEM images clearly show the QD@HEV-LPs are morphologically uniform with a mean diameter of 26 nm and narrow size distribution (**Fig. 1h**). Dynamic light scattering (DLS) analysis also confirmed the size homogeneity of QDs, HEV-LPs, and QD@HEV-LPs with a mean hydrodynamic diameter of 7.0, 36.0, and 38.0 nm, respectively (**Fig. 1i**). The comparatively small particle size distribution is in agreement with the optical measurements. X-ray diffraction (XRD) is analyzed to measure the crystal nature. The diffraction pattern of the QDs suggests that the QDs are crystalline (**Fig. 1j**), showing three characteristic peaks for (111), (220), and (311) crystal planes at 2 θ of 24.7°, 42.4°, and 50.4°, respectively (Adegoke et al., 2015). As shown in **Fig. 1k**, the synthesized amine-functionalized



Scheme 1. Schematic representation illustrating the (a) fabrication process of QDs-encapsulated the HEV-LPs (QD@HEV-LPs), and (b) target anti-HEV antibody detection principle based on antigen-antibody reaction and magnetic separation.




Fig. 1. Synthesis and characterization of QD@HEV-LPs. (a) Schematic illustration of the synthesis steps preparing the QD@HEV-LPs. The TEM images of (b) QDs, (e) HEV-LPs, (g) disassembled HEV-LPs, (h) QD@HEV-LPs, and corresponding particle size distributions of (c) QDs, (f) HEV-LPs, and (i) QD@HEV-LPs, (j) DLS measurement of QDs (black), HEV-LPs (blue), and QD@HEV-LPs (green), (d) XRD of QDs and (k) TEM image of MNPs. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

MNPs (Amine-MNPs) are spherical with a diameter range of 15 and 20 nm.

The HEV-LP proteins in the fractions of the CsCl gradient centrifugation were confirmed by western blotting analysis (Fig. 2a) and SDS-PAGE (Fig. 2b). The binding of the HEV-specific primary antibody used in western blotting corresponded to the full-length HEV-LPs (Fig. 2a) and the single band shown in Coomassie Blue staining indicates that the purification is highly efficient (Fig. 2b–i). Furthermore, SDS-PAGE confirmed that the same bands as the HEV-LPs mentioned above were obtained in each step of the preparation of QD@HEV-LPs (Fig. 2b). Fig. 2c displays the fluorescence spectra of pristine QDs and QDs@HEV-LPs. QDs@HEV-LPs show a shift in emission wavelength of around 6–8 nm concerning pristine QDs alone. We assume that the encapsulation of QDs in the viral capsid induces an increase in the effective refractive index (Dixit et al., 2006). The fluorescence intensity of QDs decreased several folds after the preparation of QD@HEV-LPs (Fig. S1) as the unencapsulated QDs are separated, and also the protein coat on the surface of the QDs might also interfere with the fluorescence intensity of the QD@HEV-LPs. The stability QDs@HEV-LP solution is evaluated by storing the prepared QDs@HEV-LP at 4 °C for 20 days by monitoring the change in fluorescence intensity periodically. As shown in Fig. S2, the fluorescence intensity of QDs@HEV-LP was stable for 10 days and recovery was determined to be 93%. After 15 and 20 days of storage, the QDs@HEV-LP can retain the original fluorescence intensity of 84 and 79%, respectively. In addition, the antibody binding affinity for HEV-LPs and QD@HEV-LPs was confirmed using a

conventional ELISA system with IgG-HRP as shown in Fig. S3. The binding affinity of QD@HEV-LPs was not decreased before and after assembly.

3.3. Feasibility of anti-HEV antibody detection using QDs@HEV-LPs

The amount of QDs used for the preparation of QDs@HEV-LPs is optimized with the fixed amount of HEV-LPs (Fig. 2d). In the case of 0.5 and 1 mg mL⁻¹ QDs concentration, the fluorescence intensity is quite satisfactory and almost saturated in higher than 1 mg mL⁻¹. The assembly reaction might contain few incompletely formed capsids and some protein/QD amorphous aggregation, resulting in increased fluorescence intensity. A similar phenomenon has been reported in the formation of VLPs with Au cores; when the cores are presenting excess, incomplete protein coverage occurs (Chen et al., 2005). Therefore, QDs concentration of 1 mg mL⁻¹ was chosen to prepare the QDs@HEV-LPs.

In addition, the fewer amount of MNPs cannot bind all the antibodies along with QDs@HEV-LPs, leading to false signals. Therefore, optimization of the MNPs concentration is also a crucial parameter in this work. A concentration of 10⁻⁹ g mL⁻¹ of anti-HEV antibody is tested with different amounts of MNPs with a fixed concentration of QDs-HEV-LPs. As shown in Fig. 2e, the magnetically isolated QDs@HEV-LPs||anti-HEV antibody||anti-R-IgG@MNPs have been tested by the fluorometric method. In the case of a low amount of anti-R-IgG@MNPs, the magnetic nanoconjugates contain a lesser amount of QDs@HEV-LPs as compared to the 1 mg, which indicates the partial attachment of QDs@HEV-LPs||




Fig. 2. Western blot of HEV-LPs (a) and SDS-PAGE of HEV-LPs (i), disassembled HEV-LPs (ii), and QD@HEV-LPs (iii) (b). (c) Fluorescent emission spectra of QDs (red) and QDs@HEV-LPs (green). Optimizations of QDs concentration on the fluorescence of prepared QD@HEV-LPs (d) and MNP concentration for the QDs@HEV-LP/anti-HEV-Ab/anti-IgG-HEV@MNPs nanoconjugates (e) in HEV antibody sensing. Error bars in d and e denote data as average $\pm$ SD ($n = 3$). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

anti-HEV antibody complex. On the other hand, a high amount of MNPs of 1.5 and 1.7 mg, though the magnetic adduct successfully separated the HEV-LPs. However, itself quenched the signal due to the QDs@HEV-LPs and MNP interaction. Therefore, optimizing all the results, 1 mg of anti-R-IgG@MNPs shows the best-optimized antibody detection condition.

3.4. Sensitivity of anti-HEV antibody detection

The quantitative measurement is performed by detecting various anti-HEV antibodies' concentrations under the optimal conditions to determine the sensitivity of the proposed fluorescence dependent biosensor. It can be seen from Fig. 3a; the fluorescence intensity increased proportionally with the increasing anti-HEV antibody concentrations from 10^{-13} g mL⁻¹ to 10^{-7} g mL⁻¹. The linear relationship between the fluorescence intensities changes and the logarithmic values of anti-HEV concentration is plotted in Fig. 3b, and the detection limit was estimated at 87 fg mL⁻¹ calculated using mean of blank sample added to 3.3 times standard deviation of the lowest concentration of target (Armbruster and Pry 2008; Ganganboina and Doong 2018, 2019; Ganganboina et al., 2018). In addition, the calibration curve shows acceptable linearity with a correlation coefficient (R^2) of 0.986. These results strongly demonstrate that the QDs@HEV-LPs-based sensor possesses a strong anti-interference ability, high accuracy, and improved sensitivity.

The anti-HEV antibody detection sensitivity of the developed QD@HEV-LPs-based sensor is competitive with recently developed sensing methods (Table S1 of Supplementary data). In our developed sensor, using QD@HEV-LPs exhibits the following benefits. VLPs containing receptor-binding domain to cell surface receptors can mimic native virus favoring the specific binding between antibody and target virus. Above all, the native conformation of antigens maintains during the detecting procedure in the solution phase. It prevents the unexpected

orientation not withholding the necessary epitopes for antibody conjugation and prevents the physical deformation of antigen after immobilization on supports. VLPs resemble native viruses, thereby providing repetitive antigens on the surface of VLPs, providing significant advantages over other antibody detection platforms. Besides being safe and efficacious, VLPs also provide the added advantage of multivalency by combining closely related VLPs in desired concentrations into a single formulation which will further help to develop multiple antibody detection using the same VLPs. In addition, ease as well as consistency of production using stable cell lines provides easy scale-up and commercialization. This is the first study demonstrating the effectiveness of QDs-encapsulated VLPs antibody detection to the best of our knowledge.

3.5. Effect of a complex matrix on anti-HEV antibody detection using QDs@HEV-LPs

To establish a reliable and practical immunoassay, a dilution series of anti-HEV antibody concentrations are spiked in the biological human serum matrix. The developed fluorometric biosensor shows a linear increase of fluorescence intensity to the function of the introduced anti-HEV antibodies in the medium (Fig. 3c). Fig. 3d shows the calibration line for anti-HEV antibody detection using the human serum as a detection medium. The gradient of the calibration line is slightly flat shifted than the linear calibration from the anti-HEV antibody detection in buffer solution up to 15%. However, the anti-HEV antibody detection's responsive linearity confirmed the applicability of the developed antibody biosensor in a sophisticated serum matrix. The interfering substances in human serum samples do not react and hamper the fluorescence intensity of QD@HEV-LPs. Prompt to the matrix effect, the calibration curve slope is flattened, increasing the LOD value 1.13 pg mL⁻¹. However, the higher LOD due to the matrix effect is considerable compared to the previously reported results for its real application (Bohm et al., 2020; Shrestha et al., 2016; Takahashi et al., 2005). In




Fig. 3. Sensitivity test of QD@HEV-LPs-based fluorometric sensor for anti-HEV antibody. (a) Change in fluorescence spectra of QD@HEV-LPs in the presence of different concentrations of anti-HEV antibodies, (b) calibration curve, change of fluorescence intensities of QD@HEV-LPs vs. anti-HEV antibody concentration, (c) fluorescence spectra, and (d) calibration curve for anti-HEV antibodies in 10% human serum as a sensing medium. (e) Selectivity test in the presence of the target anti-HEV antibody and other antibodies. Error bars in b, d and e denote data as average $\pm$ SD ($n = 3$).

addition, to evaluate the sensitivity of the developed method with traditional ELISA, we have performed the ELISA using QD@HEV-LPs and HRP-conjugated anti-rabbit IgG to detect the anti-HEV antibodies. As shown in Fig. S4, the change in absorbance from 1 pg mL⁻¹ to 1 of anti-HEV antibody can be observed. However, change in absorbance intensity of 0.1 pg mL⁻¹ of an anti-HEV is very small or almost negligible, limiting the sensitivity of ELISA using QD@HEV-LPs to 1 pg mL⁻¹. However, in the developed method, anti-HEV antibody can be detected from 1 fg mL⁻¹ to 100 ng mL⁻¹, attributing to the developed method's increased sensitivity.

3.6. Specificity of anti-HEV antibody detection

The selectivity of the developed QDs@HEV-LPs-based fluorometric biosensor for anti-HEV antibody detection is evaluated. The anti-VP28 antibody for WSSV, anti-IFV antibody (New Caledonia/20/99) (H1N1) for IFV, Anti-S protein antibody of SARS-CoV-2 obtained from rabbit, anti-NoV antibody broadly reactive to genogroup II (NS14 Ab), anti-NS1 protein antibody for ZIKV, and anti-E1 protein of CHIKV antibodies obtained from mouse are assayed as interferences (negative samples) to examine the anti-interference effect and the selectivity of the developed biosensor which is collated to the response of anti-HEV antibody. Fig. 3e

shows the change in the fluorescence intensity of the developed biosensor to the negative samples and anti-HEV antibody. The analytical signal was developed for the sample containing the only anti-HEV antibody, but not in the negative samples containing interferences only. The interfering antibodies are unrecognizable by the QDs@HEV-LPs, which are specific to the anti-HEV antibody. After magnetic separation and washing, there are no QDs@HEV-LPs in the reaction chamber, resulting in a small increase in the fluorescence intensity. The only slight increase in the analytical signal in detecting the negative samples justified the superior specificity of QDs@HEV-LPs-based fluorometric sensors towards anti-HEV antibody detection.

3.7. Detection of anti-HEV-IgG from the serum samples and RNA copy number from fecal specimens of G5-HEV-infected cynomolgus monkey

Considering the high sensitivity and accuracy of the developed method for anti-HEV antibody detection, it was further applied to evaluate the applicability in sera of G5-HEV-infected cynomolgus monkey. Sera were collected from 0 to 68 dpi. As shown in Fig. 4a, the change in fluorescence intensity started at 7 dpi, indicating that the anti-HEV antibodies were first induced at 7 dpi. Using the calibration curve established (Fig. 3b), the concentration of anti-HEV was estimated. At 7 dpi, 1.4 pg mL^{-1} of anti-HEV was found in a serum sample. The change in fluorescence intensity further increased, measuring 54.5 pg mL^{-1} of anti-HEV antibodies on the 19 dpi and then remained constant until 25 dpi. The anti-HEV antibody concentration further increased after 25 dpi and measured to be 110 pg mL^{-1} at 33 dpi, reached a plateau after 40 dpi with anti-HEV antibody concentration of 149 pg mL^{-1} .

In addition, to measure the HEV RNA concentration in G5-HEV-infected cynomolgus monkey, RNA copy numbers of fecal specimens collected from 0 to 68 dpi were measured by RT-qPCR. After the second

to third weeks, the infection peak is shown and then gradually decreased to an undetectable amount after the fourth week. As shown in Fig. 4b, the G5-HEV was detected 2.66×10^4 copies mL^{-1} in the fecal specimen on 9 dpi, and then it reached a peak of 1.54×10^6 copies mL^{-1} on 20 dpi, and it started to decrease later. The RNA copy number was undetectable after 30 dpi.

Comparison of the HEV RNA copy numbers in feces and anti-HEV antibodies concentration in serum from day 0–68 dpi (Fig. 4b), clearly shows that the infection could be controlled in the infected monkey immediately after the increase in anti-HEV IgG antibody concentration in sera after 19 dpi. The IgG concentration increased until 40 dpi and remained at high levels until 68 dpi. Resulting, no further change in HEV RNA copy numbers and remained undetected after 30 dpi in the feces samples. The anti-HEV antibody concentration detected in HEV-infected monkey using the developed fluorescence method follow the similar trend with the O.D. values measured using the gold standard ELISA technique (Li et al., 2019b), confirming the applicability of the developed sensing method for real samples. This newly developed strategy builds a useful capability for fluorescence-based convenient screening and accurate diagnosis of suspect infections.

4. Conclusions

In conclusion, we have demonstrated an effective method for assembling QD@HEV-LPs, profiting by encapsulating fluorescent QDs into HEV-LPs with high specificity for antibody detection. The unique bio-nanomaterial, QD@HEV-LPs, preserves the fluorescence of the incorporated QDs and also provides uniform dispersibility. The QD@HEV-LPs are successfully applied for the low-level anti-HEV antibody detection, using the universal antigen-antibody conjugation. The specificity for HEV antibodies is obtained from the HEV-LPs, and the




Fig. 4. G5 HEV infection in cynomolgus monkey and sensor performance. (a) Change in fluorescence of QD@HEV-LPs in the presence of sera of G5 HEV-infected cynomolgus monkey, (b) comparison of the anti-HEV IgG concentration in serum and respective G5-HEV RNA concentration in fecal specimens of G5 HEV-infected cynomolgus monkey. The sera and fecal specimens were collected at 0–68 dpi from an experimentally G5 HEV-infected cynomolgus monkey. Error bars in b, d and e denote data as average $\pm$ SD ($n = 3$).

encapsulated QDs provide analytical signals. The strong magnetic responsive ability of anti-IgG@MNPs favors the efficient separation of the target from complex samples without any pretreatment. As a result, amplified fluorescence readout from the enriched QDs@HEV-LP/anti-HEV antibody/anti-IgG@MNPs is attained. The developed fluorometric sensor can assay the HEV antibodies with a detection limit down to 87 fg mL^{-1} . The developed sensor showed excellent performance for detecting antibodies in the complex matrix without eliciting observable interference. Moreover, it is successfully applied for the detection of antibodies in sera from HEV-infected monkey. Importantly, this work is the first to investigate the QDs@HEV-LP's fluorescence behavior for biosensing platform construction and offered an efficient way for highly sensitive and selective detection anti-HEV antibody. The developed method would open up new possibilities for developing nanomaterials-loaded VLPs with suitable functions. It would benefit the advancement of nanotechnologies based on VLPs in disease diagnosis and clinical research.

Ethics declarations

The animal experiments were reviewed and approved by the National Institute of Infectious Diseases (NIID) Ethics Committee and carried out according to the "Guides for Animal Experiments Performed at NIID" under codes 110054 and 514014.

CRediT authorship contribution statement

Akhilesh Babu Ganganboina: designed this study, Writing – original draft, fabricated QD@HEV-LPs, characterized, collected, analyzed experimental data. **Kenshin Takemura:** fabricated QD@HEV-LPs, characterized, collected, analyzed experimental data. **Tian-Cheng Li:** prepared HEV-LP and provided HEV-infected sera, RT-qPCR. **Enoch Y. Park:** conceived this study, revised paper, supervised this study, All authors commended on the manuscript.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

NoV antibodies were kindly provided by Professor T. Suzuki of Department of Infectious Diseases, Hamamatsu University School of Medicine. ABG and KT sincerely thanks the Japan Society for the Promotion of Science (JSPS) for a postdoctoral fellowship (Grant Nos. 19F19064 and 20J13223).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bios.2021.113261>.

References

- Adegoke, O., Nyokong, T., Forbes, P.B., 2015. *J. Alloys Compd.* 645, 443–449.
- Aniagyei, S.E., Kennedy, C.J., Stein, B., Willits, D.A., Douglas, T., Young, M.J., De, M., Rotello, V.M., Srisathiyarayanan, D., Kao, C.C., 2009. *Nano Lett.* 9 (1), 393–398.
- Armbruster, D.A., Pry, T., 2008. *Clin. Biochem. Rev.* 29 (Suppl. 1), S49.
- Arts, R., Den Hartog, I., Zijlema, S.E., Thijssen, V., van der Beelen, S.H., Merckx, M., 2016. *Anal. Chem.* 88 (8), 4525–4532.
- Bohm, K., Strömpl, J., Krumbholz, A., Zell, R., Krause, G., Sievers, C., 2020. *J. Clin. Microbiol.* 58 (2) e01029-19.
- Brasch, M., Putri, R.M., de Ruiter, M.V., Luque, D., Koay, M.S., Castón, J.R., Cornelissen, J.J., 2017. *J. Am. Chem. Soc.* 139 (4), 1512–1519.
- Chen, C., Kwak, E.-S., Stein, B., Kao, C.C., Dragnea, B., 2005. *J. Nanosci. Nanotechnol.* 5 (12), 2029–2033.
- Chowdhury, A.D., Ganganboina, A.B., Tsai, Y.-C., Chiu, H.-C., Doong, R.-a., 2018. *Anal. Chim. Acta* 1027, 109–120.
- Dang, V.D., Ganganboina, A.B., Doong, R.-A., 2020. *ACS Appl. Mater. Interfaces* 12 (29), 32247–32258.
- Dixit, S.K., Goicochea, N.L., Daniel, M.-C., Murali, A., Bronstein, L., De, M., Stein, B., Rotello, V.M., Kao, C.C., Dragnea, B., 2006. *Nano Lett.* 6 (9), 1993–1999.
- Dragnea, B., Chen, C., Kwak, E.-S., Stein, B., Kao, C.C., 2003. *J. Am. Chem. Soc.* 125 (21), 6374–6375.
- Dutta Chowdhury, A., Ganganboina, A.B., Nasrin, F., Takemura, K., Doong, R.-a., Utomo, D.I.S., Lee, J., Khoris, I.M., Park, E.Y., 2018. *Anal. Chem.* 90 (21), 12464–12474.
- Ganganboina, A.B., Doong, R.-a., 2018. *Sens. Actuators, B* 273, 1179–1186.
- Ganganboina, A.B., Doong, R.-A., 2019. *Sci. Rep.* 9 (1), 7214.
- Ganganboina, A.B., Dutta Chowdhury, A., Doong, R.-a., 2018. *ACS Appl. Mater. Interfaces* 10 (1), 614–624.
- Ganganboina, A.B., Chowdhury, A.D., Khoris, I.M., Doong, R.-a., Li, T.-C., Hara, T., Abe, F., Suzuki, T., Park, E.Y., 2020a. *Biosens. Bioelectron.* 170, 112680.
- Ganganboina, A.B., Chowdhury, A.D., Khoris, I.M., Nasrin, F., Takemura, K., Hara, T., Abe, F., Suzuki, T., Park, E.Y., 2020b. *Biosens. Bioelectron.* 157, 112169.
- Ganganboina, A.B., Khoris, I.M., Chowdhury, A.D., Li, T.-C., Park, E.Y., 2020c. *ACS Appl. Mater. Interfaces* 12 (45), 50212–50221.
- Herbert, F.C., Brohlin, O.R., Galbraith, T., Benjamin, C., Reyes, C.A., Luzuriaga, M.A., Shahrivarkevishahi, A., Gassensmith, J.J., 2020. *Bioconjugate Chem.* 31 (5), 1529–1536.
- Iverson, G.M., Matsuura, E., Victoria, E.J., Cockerill, K.A., Linnik, M.D., 2002. *J. Autoimmun.* 18 (4), 289–297.
- Lei, Y.-M., Zhou, J., Chai, Y.-Q., Zhuo, Y., Yuan, R., 2018. *Anal. Chem.* 90 (20), 12270–12277.
- Li, T.-C., Yamakawa, Y., Suzuki, K., Tatsumi, M., Razak, M., Uchida, T., Takeda, N., Miyamura, T., 1997. *J. Virol.* 71 (10), 7207–7213.
- Li, T.-C., Yoshimatsu, K., Yasuda, S.P., Arikawa, J., Koma, T., Kataoka, M., Ami, Y., Suzuki, Y., Mai, L.T.Q., Hoa, N.T., 2011. *J. Gen. Virol.* 92 (Pt 12), 2830.
- Li, L., Xu, C., Zhang, W., Secundo, F., Li, C., Zhang, Z.-P., Zhang, X.-E., Li, F., 2019a. *Nano Lett.* 19 (4), 2700–2706.
- Li, T.-C., Bai, H., Yoshizaki, S., Ami, Y., Suzuki, Y., Doan, Y.H., Takahashi, K., Mishihiro, S., Takeda, N., Wakita, T., 2019b. *Hepatol. Commun.* 3 (1), 160–172.
- Liu, Z., Qiao, J., Niu, Z., Wang, Q., 2012. *Chem. Soc. Rev.* 41 (18), 6178–6194.
- Liu, Y., Nie, Y., Wang, M., Zhang, Q., Ma, Q., 2020. *Biosens. Bioelectron.* 148, 111823.
- Ma, Y., Nolte, R.J., Cornelissen, J.J., 2012. *Adv. Drug Deliv. Rev.* 64 (9), 811–825.
- Michalet, X., Pinaud, F.F., Bentolila, L.A., Tsay, J.M., Doose, S., Li, J.J., Sundaresan, G., Wu, A., Gambhir, S., Weiss, S., 2005. *Science* 307 (5709), 538–544.
- Qi, H., Zhang, C., 2020. *Anal. Chem.* 92 (1), 524–534, 2020.
- Robinson, D.A., Stevenson, K.J., 2013. *J. Mater. Chem.* 1 (43), 13443–13453.
- Sasaki, E., Dragoman, R.M., Mantri, S., Dirin, D.N., Kovalenko, M.V., Hilvert, D., 2020. *ChemBiochem* 21 (1–2), 74–79.
- Shrestha, A.C., Flower, R.L., Seed, C.R., Stramer, S.L., Faddy, H.M., 2016. *J. Blood Transfus.* 47 (2), 97–100.
- Tagit, O., De Ruiter, M., Brasch, M., Ma, Y., Cornelissen, J., 2017. *RSC Adv.* 7 (60), 38110–38118.
- Takahashi, M., Kusakai, S., Mizuo, H., Suzuki, K., Fujimura, K., Masuko, K., Sugai, Y., Aikawa, T., Nishizawa, T., Okamoto, H., 2005. *J. Clin. Microbiol.* 43 (1), 49–56.
- Takamura, S., Niikura, M., Li, T., Takeda, N., Kusagawa, S., Takebe, Y., Miyamura, T., Yasutomi, Y., 2004. *Gene Ther.* 11 (7), 628–635.
- Tsai, C.-t., Robinson, P.V., Spencer, C.A., Bertozzi, C.R., 2016. *ACS Cent. Sci.* 2 (3), 139–147.
- Wen, A.M., Steinmetz, N.F., 2016. *Chem. Soc. Rev.* 45 (15), 4074–4126.
- Wenzel, J.J., Preiss, J., Schemmerer, M., Huber, B., Jilg, W., 2013. *J. Infect. Dis.* 207 (3), 497–500.
- World Health Organization, W.H., 2015. *Weekly Epidemiol. Record Relevé épidémiol. Hebdomadaire* 90 (18), 185–200.
- Yan, D., Wang, B., Sun, S., Feng, X., Jin, Y., Yao, X., Cao, S., Guo, H., 2015. *PloS One* 10 (9), e0138883.
- Yang, D., Qiu, Z., Cui, W., Shen, Z., Liu, W., Hu, H., Jin, M., Li, J.-W., 2017. *Nanotechnol. Lett.* 9 (12), 2119–2125.
- Yang, Y.-B., Tang, Y.-D., Hu, Y., Yu, F., Xiong, J.-Y., Sun, M.-X., Lyu, C., Peng, J.-M., Tian, Z.-J., Cai, X.-H., 2020. *Nano Lett.* 20 (2), 1417–1427.
- Zafrullah, M., Zhang, X., Tran, C., Nguyen, M., Kamili, S., Purdy, M.A., Stramer, S.L., 2018. *Transfusion* 58 (5), 1254–1263.
- Zhang, B., Kumar, R.B., Dai, H., Feldman, B.J., 2014. *Nat. Med.* 20 (8), 948–953.